Long-term humoral signatures following acute pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

التفاصيل البيبلوغرافية
العنوان:	Long-term humoral signatures following acute pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
المؤلفون:	Burns MD; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA., Bartsch YC; Harvard Medical School, Boston, MA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Davis JP; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA., Boribong BP; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Loiselle M; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA., Kang J; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Kane AS; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA., Edlow AG; Harvard Medical School, Boston, MA, USA.; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA., Fasano A; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Alter G; Harvard Medical School, Boston, MA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Yonker LM; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA. Lyonker@mgh.harvard.edu.; Department of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA. Lyonker@mgh.harvard.edu.; Harvard Medical School, Boston, MA, USA. Lyonker@mgh.harvard.edu.
المصدر:	Pediatric research [Pediatr Res] 2023 Oct; Vol. 94 (4), pp. 1327-1334. Date of Electronic Publication: 2023 May 12.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 0100714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0447 (Electronic) Linking ISSN: 00313998 NLM ISO Abbreviation: Pediatr Res Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2012- : New York : Nature Publishing Group Original Publication: Basel ; New York : Karger.
مواضيع طبية MeSH:	COVID-19*/diagnosis, Young Adult ; Child ; Humans ; SARS-CoV-2 ; Acute Disease ; Systemic Inflammatory Response Syndrome/diagnosis ; Cytokines ; Antibodies, Viral
مستخلص:	Background: Although most children experience mild symptoms during acute SARS-CoV-2 infection, some develop the severe post-COVID-19 complication, Multisystem Inflammatory Syndrome in Children (MIS-C). While acute presentations of COVID-19 and MIS-C have been well immunophenotyped, little is known about the lasting immune profile in children after acute illness. Methods: Children 2 months-20 years of age presenting with either acute COVID-19 (n = 9) or MIS-C (n = 12) were enrolled in a Pediatric COVID-19 Biorepository at a single medical center. We deeply profiled humoral immune responses and circulating cytokines following pediatric COVID-19 and MIS-C. Results: Twenty-one children and young adults provided blood samples at both acute presentation and 6-month follow-up (mean: 6.5 months; standard deviation: 1.77 months). Pro-inflammatory cytokine elevations resolved after both acute COVID-19 and MIS-C. Humoral profiles continue to mature after acute COVID-19, displaying decreasing IgM and increasing IgG over time, as well as stronger effector functions, including antibody-dependent monocyte activation. In contrast, MIS-C immune signatures, especially anti-Spike IgG1, diminished over time. Conclusions: Here, we show the mature immune signature after pediatric COVID-19 and MIS-C, displaying resolving inflammation with recalibration of the humoral responses. These humoral profiles highlight immune activation and vulnerabilities over time in these pediatric post-infectious cohorts. Impact: The pediatric immune profile matures after both COVID-19 and MIS-C, suggesting a diversified anti-SARS-CoV-2 antibody response after resolution of acute illness. While pro-inflammatory cytokine responses resolve in the months following acute infection in both conditions, antibody-activated responses remain relatively heightened in convalescent COVID-19. These data may inform long-term immunoprotection from reinfection in children with past SARS-CoV-2 infections or MIS-C. (© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.)
References:	Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383, 334–346 (2020). (PMID: 10.1056/NEJMoa202168032598831) Stephenson, T. et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ Open 11, e052838 (2021). (PMID: 10.1136/bmjopen-2021-05283834446502) Soriano, J. B. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102–e107 (2022). (PMID: 10.1016/S1473-3099(21)00703-934951953) Buonsenso, D. et al. Preliminary evidence on long COVID in children. Acta Paediatr. 110, 2208–2211 (2021). (PMID: 10.1111/apa.15870338355078251440) Sacco, K. et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat. Med. 28, 1050–1062 (2022). (PMID: 10.1038/s41591-022-01724-3351778629119950) Yonker, L. M. et al. Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J. Pediatr. 227, 45.e5–52.e5 (2020). (PMID: 10.1016/j.jpeds.2020.08.037) Bartsch, Y. C. et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat. Med. 27, 454–462 (2021). (PMID: 10.1038/s41591-021-01263-3335898258315827) Cotugno, N. et al. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. Cell Rep. 34, 108852 (2021). (PMID: 10.1016/j.celrep.2021.108852337305807962998) Feldstein, L. R. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325, 1074–1087 (2021). (PMID: 10.1001/jama.2021.209133625505) Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 22, 25–31 (2021). (PMID: 10.1038/s41590-020-00826-933154590) Porritt, R. A. et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J. Clin. Investig. 131, e151520 (2021). (PMID: 10.1172/JCI151520344373038516454) Vella, L. A. et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci. Immunol. 6, eabf7570 (2021). (PMID: 10.1126/sciimmunol.abf7570336539078128303) Lima, R. et al. Establishment of a pediatric COVID-19 biorepository: unique considerations and opportunities for studying the impact of the COVID-19 pandemic on children. BMC Med. Res. Methodol. 20, 228 (2020). (PMID: 10.1186/s12874-020-01110-y329171417483494) Yonker, L. M. et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Investig. 131, e149633 (2021). (PMID: 10.1172/JCI149633340326358279585) Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855–864 (2021). (PMID: 10.1001/jama.2021.069433523115) Lapp, S. A. et al. Serologic and cytokine signatures in children with multisystem inflammatory syndrome and coronavirus disease 2019. Open Forum Infect. Dis. 9, ofac070 (2022). (PMID: 10.1093/ofid/ofac070352377038883592) Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020). (PMID: 10.1038/s41591-020-0897-132350462) Porritt, R. A. et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J. Clin. Investig. 131, e146614 (2021). (PMID: 10.1172/JCI146614337053598121516) Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Medicine 3, 371–387.e379 (2022). (PMID: 10.1016/j.medj.2022.04.001) Ashkenazi-Hoffnung, L. et al. Long COVID in children: observations from a designated pediatric clinic. Pediatr. Infect. Dis. J. 40, e509–e511 (2021). (PMID: 10.1097/INF.0000000000003285343715078575093) Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur. J. Pediatr. 181, 1597–1607 (2022). (PMID: 10.1007/s00431-021-04345-z350000038742700) Swank, Z. et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin. Infect. Dis. 76, e487–e490 (2023). Bartsch, Y. C. et al. SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Sci. Transl. Med. 14, eabn9237 (2022). Levy, M. et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA 327, 281–283 (2022). (PMID: 10.1001/jama.2021.2326234928295) Olson, S. M. et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N. Engl. J. Med. 386, 713–723 (2022). (PMID: 10.1056/NEJMoa211799535021004) Zambrano, L. D. et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021. MMWR Morb. Mortal. Wkly Rep. 71, 52–58 (2022). (PMID: 10.15585/mmwr.mm7102e1350258528757620) Wallukat, G. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 4, 100100 (2021). (PMID: 10.1016/j.jtauto.2021.100100338804428049853) Son, K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 61, 2200970 (2023). (PMID: 36137590) Muri, J. et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat. Immunol. 24, 604–611 (2023). (PMID: 10.1038/s41590-023-01445-w3687906710063443)
المشرفين على المادة:	0 (Cytokines) 0 (Antibodies, Viral)
SCR Disease Name:	pediatric multisystem inflammatory disease, COVID-19 related
تواريخ الأحداث:	Date Created: 20230512 Date Completed: 20231221 Latest Revision: 20231221
رمز التحديث:	20231221
مُعرف محوري في PubMed:	PMC10176275
DOI:	10.1038/s41390-023-02627-w
PMID:	37173406
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1530-0447
DOI:	10.1038/s41390-023-02627-w